|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2009-10-13
|
|
pubmed:abstractText |
Fulvestrant is a pure anti-estrogen hormoal agent formally lacking any estrogen-agonist activity. We analyze the effect(s) of fulvestrant treatment on estrogen target systems in hormoe-sensitive advanced breast cancer patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/fulvestrant
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1555-8576
|
|
pubmed:author |
pubmed-author:AmorosoDomenicoD,
pubmed-author:CameriniAndreaA,
pubmed-author:DonatiSaraS,
pubmed-author:GarroneOrnellaO,
pubmed-author:MattiotValentina PollaVP,
pubmed-author:PortaRomana ProsperiRP,
pubmed-author:PuccettiChetiC,
pubmed-author:PuccinelliPaoloP,
pubmed-author:RondiniMariannaM,
pubmed-author:SgambatoAlessandroA,
pubmed-author:SiclariOlimpiaO,
pubmed-author:TartarelliGiannaG,
pubmed-author:ValsuaniChiaraC,
pubmed-author:VincentiMauraM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1450-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19556864-Adenocarcinoma,
pubmed-meshheading:19556864-Aged,
pubmed-meshheading:19556864-Aged, 80 and over,
pubmed-meshheading:19556864-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19556864-Aromatase Inhibitors,
pubmed-meshheading:19556864-Breast Neoplasms,
pubmed-meshheading:19556864-Cholesterol,
pubmed-meshheading:19556864-Cholesterol, LDL,
pubmed-meshheading:19556864-Endometrium,
pubmed-meshheading:19556864-Estradiol,
pubmed-meshheading:19556864-Estrogen Receptor Modulators,
pubmed-meshheading:19556864-Estrogens,
pubmed-meshheading:19556864-Female,
pubmed-meshheading:19556864-Humans,
pubmed-meshheading:19556864-Lipid Metabolism,
pubmed-meshheading:19556864-Middle Aged,
pubmed-meshheading:19556864-Neoplasm Proteins,
pubmed-meshheading:19556864-Neoplasms, Hormone-Dependent,
pubmed-meshheading:19556864-Postmenopause,
pubmed-meshheading:19556864-Progesterone,
pubmed-meshheading:19556864-Prospective Studies,
pubmed-meshheading:19556864-Receptors, Estrogen,
pubmed-meshheading:19556864-Receptors, Progesterone,
pubmed-meshheading:19556864-Triglycerides
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
|
|
pubmed:affiliation |
Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Italy. andreacamerini@katamail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
